Search results for "Ophthalmology"

showing 10 items of 1738 documents

Uveítis anterior aguda hipertensiva granulomatosa bilateral como efecto adverso a brimonidina tópica

2018

Abstract Clinical case The case concerns an 81-year-old woman on treatment with a topical fixed combination of timolol and brimonidine who was diagnosed in the Emergency Department with acute anterior granulomatous hypertensive uveitis. The patient responded favorably to the withdrawal of the eye drops without showing any subsequent relapse. Discussion Uveitis due to brimonidine is a rare adverse effect, but it must be known. Once the diagnosis is suspected, the effective treatment is the withdrawal of brimonidine, with or without the addition of topical corticosteroids to control inflammation depending on the severity of the condition. It is a process with an excellent prognosis.

medicine.medical_specialtySubsequent RelapseSide effectbusiness.industryBrimonidineTimololEmergency departmentmedicine.diseaseDermatology03 medical and health sciencesOphthalmology0302 clinical medicine030221 ophthalmology & optometrymedicineAnterior uveitisAdverse effectbusiness030217 neurology & neurosurgeryUveitismedicine.drugArchivos de la Sociedad Española de Oftalmología
researchProduct

Modulation of central corneal thickness by various riboflavin eyedrop compositions in porcine corneas

2012

Purpose To evaluate the modulatory effect of various riboflavin 0.1% and 0.2% compositions on the central corneal thickness (CCT) in fresh porcine corneas. Setting Department of Ophthalmology, Johannes Gutenberg University of Mainz, Mainz, Germany. Design Experimental study. Methods The CCT in freshly enucleated porcine globes was measured by ultrasound pachymetry before and after (if applicable) deepithelialization and every 10 minutes thereafter during 120 minutes of eyedrop application. In Groups 1 and 2 (controls), no eyedrops were applied. In Groups 3 and 4, isotonic riboflavin eyedrops were used. In Groups 5 to 9, hypotonic riboflavin eyedrops were given. In Groups 10 and 11, preparat…

medicine.medical_specialtySwineRiboflavinRiboflavinCorneaCorneal edemaCorneaOphthalmologyIsotonicAnimalsMedicineBody Weights and MeasuresUltrasonographyPhotosensitizing Agentsbusiness.industryCorneal EdemaOsmolar ConcentrationUltrasound pachymetryHydrogen-Ion ConcentrationSensory SystemsSurgeryOphthalmologyCross-Linking ReagentsOphthalmic solutionsmedicine.anatomical_structurePhotochemotherapySurgeryOphthalmic SolutionsbusinessJournal of Cataract and Refractive Surgery
researchProduct

Morbus Eales – 10 Jahre Erfahrung mit einem seltenen Krankheitsbild

2009

BACKGROUND: Eales’ disease is an uncommon vasoproliferative retinal disease affecting otherwise healthy young men. We report on our treatment results in a large patients group with long-term follow-up. PATIENTS AND METHODS: The treatment results in 50 eyes (35 patients) with Eales’ disease, that were cosecutively treated from May 1995 to August 2005, were analysed retrospectively. Recorded data included age, sex, race, association of systemic disease, medications, laboratory evaluation and the surgical treatment. Mean follow-up was 5.8 years (minimum: 3.2, maximum: 8.6 years). RESULTS: Systemic and laboratory evaluations detected a factor V Leiden mutation (4 × ), vestibuloauditory problems…

medicine.medical_specialtySystemic diseaseVisual acuitygenetic structuresbusiness.industrymedicine.medical_treatmentVitrectomyRetinalmedicine.diseaseeye diseasesSurgeryOphthalmologychemistry.chemical_compoundchemistryEales diseasemedicineCoagulopathyFactor V Leidenmedicine.symptomVasculitisbusinessKlinische Monatsblätter für Augenheilkunde
researchProduct

Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment.

2005

The aim of this study was to identify research avenues that might improve patient compliance with glaucoma therapy.500 patients and physicians were interviewed by telephone in 5 European countries, and the results were compiled and evaluated by 2 independent physicians.Most physicians believed that pressure reduction is useful (UK (96%), France (94%), Spain (80%), Italy (72%), and Germany (70%), p0.0001). The majority of physicians believed that noncompliance exists in 0%-25% of patients, whereas 34% of patients admitted to noncompliance. Physicians believed patients would prefer once-daily dosing (92%) and that it would help compliance, whereas 60% of patients preferred once-daily dosing, …

medicine.medical_specialtyTime FactorsVisual impairmentGlaucomaDrug complianceCompliance (psychology)Patient Education as TopicmedicineHumansPharmacology (medical)DosingPatient complianceRoyaume uniIntraocular PressurePharmacologyPressure reductionPhysician-Patient Relationsbusiness.industryData CollectionGlaucomamedicine.diseaseSurgeryEuropeOphthalmologyEmergency medicinePatient Compliancemedicine.symptomOphthalmic SolutionsbusinessAttitude to HealthJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

Three-Year Results of Hydrus Microstent with Phacoemulsification

2019

Abstract We report the 3-year IOP efficacy of the implantation of the Schlemm’s canal Hydrus® Microstent (Ivantis®) combined with phacoemulsification versus phacoemulsification alone

medicine.medical_specialtyTime Factorsgenetic structuresmedicine.medical_treatmentGlaucoma01 natural sciencesCataract03 medical and health sciences0302 clinical medicineOphthalmologymedicineHumansSingle-Blind MethodProspective Studies0101 mathematicsGlaucoma Drainage ImplantsMiniaturizationPhacoemulsificationbusiness.industry010102 general mathematicsGlaucomaGeneral MedicinePhacoemulsificationmedicine.diseaseeye diseasesTreatment Outcome030221 ophthalmology & optometryStentssense organsbusinessFollow-Up Studies
researchProduct

The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study

2016

Aims Sex hormones could provide a future treatment avenue for dry eye post menopause. However, there are few well-controlled studies. This study investigates the impact of testosterone and oestrogen on dry eye symptoms and signs in postmenopausal women. Methods A randomised double-blind placebo-controlled pilot study was conducted involving 40 women with dry eye (age 63.9±5.1 years, 13.2±6.3 years post menopause). Ten women were assigned to each of four treatment groups: transdermal testosterone, oestradiol, testosterone/oestradiol combination and placebo. Assessment at baseline and after 8 weeks: ocular symptoms, tear osmolarity, tear stability, tear secretion, meibomian gland assessment, …

medicine.medical_specialtyTime Factorsmedicine.drug_classMeibomian glandPhysiologyPilot ProjectsAdministration CutaneousPlacebo03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicineDehydroepiandrosterone sulfateDouble-Blind MethodInternal medicineHumansMedicineTestosteroneTear secretionRetrospective Studies030219 obstetrics & reproductive medicinebusiness.industryMeibomian GlandsEstrogensTestosterone (patch)Middle AgedAndrogeneye diseasesSensory SystemsPostmenopauseOphthalmologyTreatment Outcomemedicine.anatomical_structureEndocrinologychemistryTearsAndrogens030221 ophthalmology & optometryTearsDry Eye SyndromesFemalesense organsbusinessFollow-Up StudiesHormoneBritish Journal of Ophthalmology
researchProduct

Intravitreal dexamethasone implant for cystoid macular edema and inflammation after scleral buckling

2015

Purpose Cystoid macular edema may occur following scleral buckling and therefore deteriorate the visual outcome. Inflammation may be the major causative factor in the development of postoperative cystoid macular edema. This case demonstrates the effectiveness of a dexamethasone implant as a treatment after the onset of choroidal inflammation and cystoid macular edema 6 months following scleral buckling and having visual acuity restored. Methods A 59-year-old phakic woman treated with scleral buckling for macula-off retinal detachment presented 2 months after surgery with cystoid macular edema with choroidal inflammation. Optical coherence tomography and fluorescein angiography were performe…

medicine.medical_specialtyTriamcinolone acetonideVisual acuityChoroiditisgenetic structuresVisual AcuityTriamcinolone AcetonideDrug ImplantDexamethasoneMacular EdemaChoroiditiPostoperative ComplicationsGlucocorticoidOptical coherence tomographyOphthalmologyChoroidal inflammationMedicineHumansFluorescein AngiographyMacular edemaGlucocorticoidsDexamethasoneDrug Implantsmedicine.diagnostic_testbusiness.industryIntravitreal InjectionRetinal DetachmentRetinal detachmentGeneral MedicineIntravitreal dexamethasone implantMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesOphthalmologyScleral BucklingIntravitreal InjectionsFemalesense organsImplantPostoperative Complicationmedicine.symptombusinessCystoid macular edemaTomography Optical Coherencemedicine.drugHuman
researchProduct

Beals–Hecht syndrome and choroidal neovascularization

2010

PURPOSE To describe a case of choroidal neovascularization (CNV) in a female diagnosed with Beals-Hecht syndrome. METHODS A retrospective, interventional case is described in a 26-year-old female complaining of metamorphopsia and visual loss in her left eye (counting fingers). The fluorescein angiogram and the optical coherence tomography supported the diagnosis of CNV. Intravitreal ranibizumab was administered. RESULTS After the third intravitreal ranibizumab, her visual acuity improved to 0.8 and the morphology of the macular area was restored. CONCLUSIONS To our knowledge this is the first report of CNV in Beals-Hecht syndrome treated with ranibizumab. Self-monitoring by periodically per…

medicine.medical_specialtyVisual acuityAmsler gridgenetic structuresmedicine.diagnostic_testbusiness.industryeye diseasesOphthalmologyChoroidal neovascularizationOptical coherence tomographyOphthalmologyBeals-Hecht syndromeMedicineFluorescein angiogramMetamorphopsiasense organsRanibizumabmedicine.symptombusinessmedicine.drugClinical Ophthalmology
researchProduct

Visual processing in patients with age-related macular degeneration performing a face detection test

2017

Purpose: People with age-related macular degeneration (AMD) have difficulties in familiar face recognition and facial expression discrimination. Our aim was to evaluate the visual processing of faces in AMD patients and whether this would be improved by anti-vascular endothelial growth factor therapy. This was a prospective interventional cohort study. Patients: Twelve patients with monocular wet AMD and 6 control subjects were recruited. Face detection processes were studied using cortical event-related potentials (ERPs). Patients received 3 bevacizumab intravitreal injections to the single affected eye. At baseline and 4–6 weeks after the last injection, clinical presentation and ERPs of …

medicine.medical_specialtyVisual acuityBevacizumabgenetic structuresfacial expressionsElectroencephalographybevacizumabfacial recognitionVisual processing03 medical and health sciences0302 clinical medicineOphthalmologymedicineilmeetEEGage-related eye diseasesFace detectionta315tunnistaminenOriginal ResearchFacial expressionMonocularmedicine.diagnostic_testbusiness.industryvisuaalisuuseye diseasesta3141Clinical OphthalmologyMacular degenerationRE1-994medicine.diseaseeye diseasesOphthalmologyvisualityN170silmätaudit030221 ophthalmology & optometrysense organsmedicine.symptomrecognitionbusiness030217 neurology & neurosurgerykasvontunnistus (tietotekniikka)medicine.drugface recognitionClinical Ophthalmology
researchProduct

Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or comb…

2021

Purpose Ranibizumab monotherapy showed stronger effects on area of retinal neovascularization (NV) reduction while offering better visual acuity (VA) results than panretinal laser photocoagulation (PRP) monotherapy during the first 12 months of the PRIDE study. The second year of PRIDE was an observational, non-interventional follow-up, performed to evaluate long-term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real-life conditions, prior to the approval of ranibizumab for PDR. Methods Seventy-three PDR patients (28 from the ranibizumab group; 20 from the PRP group; 25 from the combination group) were included in the observational follow-up …

medicine.medical_specialtyVisual acuityCombination therapyVisual AcuityAngiogenesis InhibitorsLight CoagulationPanretinal laser photocoagulation03 medical and health sciencesRetinal neovascularization0302 clinical medicineOphthalmologyRanibizumabMedicineHumansDiabetic Retinopathybusiness.industryGeneral MedicineDiabetic retinopathymedicine.diseaseCombined Modality TherapyDiscontinuationOphthalmologyIntravitreal Injections030221 ophthalmology & optometryObservational studyRanibizumabmedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesActa ophthalmologicaReferences
researchProduct